| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash used in operating activities | -12,596 | -10,000 |
| Purchases of property and equipment | 4 | 4 |
| Net cash used in investing activities | -4 | -4 |
| Proceeds from issuance of at-the-market shares, net | - | 84 |
| Proceeds from issuance of shares, net-At Market Offering | 168 | - |
| Proceeds from issuance of public offering shares, net | - | 18,346 |
| Proceeds from issuance of shares, net-Public Offering | 18,346 | - |
| Net cash provided by financing activities | 18,514 | 18,430 |
| Net increase (decrease) in cash | 5,914 | 8,426 |
| Cash and cash equivalents at beginning of period | 13 | - |
| Cash and cash equivalents at end of period | 5,927 | - |
AEON Biopharma, Inc. (AEON)
AEON Biopharma, Inc. (AEON)